EGFR and non-small cell lung carcinoma: Given that multiple gene alterations were detected in our study and that prior studies have observed intrapatient heterogeneity of resistance mechanisms in NSCLC patients with EGFR mutations, we hypothesized that the mutations coexisting with T790M may impact the efficacy of treatment with third-generation EGFR-TKIs.